spacer
home > pmps > winter 2020 > transdermal delivery systems
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Transdermal Delivery Systems




Transdermal delivery systems (TDS) are complex combination products typically composed of multilayer polymer components designed to deliver drugs systemically. As a result of their complex design and unique dosing requirements, designing and executing extractable and leachable (E&L) studies can be a unique challenge. One of the biggest hurdles has been the overall lack of direct regulatory guidance in the development of study designs requiring the sponsors of drug products to make regulatory justifications. Until recently, the main regulatory guidance for E&L for container/closure systems was the 1999 guidance, which included the table that correlates the likelihood that leachables would occur and the risk associated with the route of administration – which clearly ranks transdermal delivery systems as a high risk for both the potential for leachables and the route of administration (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dr Wayland Rushing has 20 years of chemical, manufacturing, and controls (CMC) analytical testing experience, including over 15 years of experience in E&L programmes. As the Director of Scientific Affairs, he is responsible for designing and implementing CMC testing programmes for Eurofins clients, including E&L programmes for pressurised metered dose inhalers, dry powder inhalers, nebulisers, and prefilled syringes, along with a variety of other drug delivery and container/closure systems. He earned his Bachelor’s degree from Westminster College, US, and his PhD in Chemistry from the University of Missouri, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI announces new pharma events calendar for 2020

Amsterdam, 17 March 2020: The CPhI Pharma portfolio confirms new exhibition dates for CPhI Japan, CPhI South East Asia and CPhI North America. Following a detailed review of attendee requirements and event feasibility, the organizers have moved quickly to secure new dates for three editions of the CPhI pharma series.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement